<SEC-DOCUMENT>0001193125-14-429659.txt : 20141202
<SEC-HEADER>0001193125-14-429659.hdr.sgml : 20141202
<ACCEPTANCE-DATETIME>20141201175053
ACCESSION NUMBER:		0001193125-14-429659
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20141202
DATE AS OF CHANGE:		20141201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-187508
		FILM NUMBER:		141258708

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d829217d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement No. 24</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>(to
Prospectus dated May&nbsp;30, 2013)</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(4) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No. 333-187508 </B></P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>125,000 Shares of Series A Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12,500,000 Shares of Common Stock Underlying the Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase up to 6,250,000 Shares of Common Stock and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6,250,000 Shares of Common Stock Underlying the Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g829217img001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement supplements the prospectus dated May&nbsp;30, 2013 (the &#147;Prospectus&#148;), as supplemented by that certain
Prospectus Supplement No.&nbsp;1 dated July&nbsp;17, 2013 (&#147;Supplement No.&nbsp;1&#148;), by that certain Prospectus Supplement No.&nbsp;2 dated July&nbsp;19, 2013 (&#147;Supplement No.&nbsp;2&#148;), by that certain Prospectus Supplement
No.&nbsp;3 dated July&nbsp;24, 2013 (&#147;Supplement No.&nbsp;3&#148;), by that certain Prospectus Supplement No.&nbsp;4 dated July&nbsp;30, 2013 (&#147;Supplement No.&nbsp;4&#148;), by that certain Prospectus Supplement No.&nbsp;5 dated
August&nbsp;6, 2013 (&#147;Supplement No.&nbsp;5&#148;), by that certain Prospectus Supplement No.&nbsp;6 dated September&nbsp;4, 2013 (&#147;Supplement No.&nbsp;6&#148;), by that certain Prospectus Supplement No.&nbsp;7 dated September&nbsp;23,
2013 (&#147;Supplement No.&nbsp;7&#148;), by that certain Prospectus Supplement No.&nbsp;8 dated October&nbsp;29, 2013 (&#147;Supplement No.&nbsp;8&#148;), by that certain Prospectus Supplement No.&nbsp;9 dated November&nbsp;6, 2013
(&#147;Supplement No.&nbsp;9&#148;), by that certain Prospectus Supplement No.&nbsp;10 dated November&nbsp;13, 2013 (&#147;Supplement No.&nbsp;10&#148;), by that certain Prospectus Supplement No.&nbsp;11 dated November&nbsp;21, 2013
(&#147;Supplement No.&nbsp;11&#148;), by that certain Prospectus Supplement No.&nbsp;12 dated December&nbsp;5, 2013 (&#147;Supplement No.&nbsp;12&#148;), by that certain Prospectus Supplement No.&nbsp;13 dated January&nbsp;8, 2014 (&#147;Supplement
No.&nbsp;13&#148;), by that certain Prospectus Supplement No.&nbsp;14 dated February&nbsp;10, 2014 (&#147;Supplement No.&nbsp;14&#148;), by that certain Prospectus Supplement No.&nbsp;15 dated February&nbsp;12, 2014 (&#147;Supplement
No.&nbsp;15&#148;), by that certain Prospectus Supplement No.&nbsp;16 dated February&nbsp;18, 2014 (&#147;Supplement No.&nbsp;16&#148;), by that certain Prospectus Supplement No.&nbsp;17 dated March&nbsp;3, 2014 (&#147;Supplement No.&nbsp;17&#148;),
by that certain Prospectus Supplement No.&nbsp;18 dated March&nbsp;20, 2014 (&#147;Supplement No.&nbsp;18&#148;), by that certain Prospectus Supplement No.&nbsp;19 dated May&nbsp;13, 2014 (&#147;Supplement No.&nbsp;19&#148;), by that certain
Prospectus Supplement No.&nbsp;20 dated June&nbsp;9, 2014 (&#147;Supplement No.&nbsp;20&#148;), by that certain Prospectus Supplement No.&nbsp;21 dated August&nbsp;13, 2014 (&#147;Supplement No.&nbsp;21&#148;), by that certain Prospectus Supplement
No.&nbsp;22 dated August&nbsp;18, 2014 (&#147;Supplement No.&nbsp;22&#148;), and by that certain Prospectus Supplement No.&nbsp;23 dated November&nbsp;12, 2014 (&#147;Supplement No.&nbsp;23&#148;, and together with Supplement No.&nbsp;1, Supplement
No.&nbsp;2, Supplement No.&nbsp;3, Supplement No.&nbsp;4, Supplement No.&nbsp;5, Supplement No.&nbsp;6, Supplement No.&nbsp;7, Supplement No.&nbsp;8, Supplement No.&nbsp;9, Supplement No.&nbsp;10, Supplement No.&nbsp;11, Supplement No.&nbsp;12,
Supplement No.&nbsp;13, Supplement No.&nbsp;14, Supplement No.&nbsp;15, Supplement No.&nbsp;16, Supplement No.&nbsp;17, Supplement No.&nbsp;18, Supplement No.&nbsp;19, Supplement No.&nbsp;20, Supplement No.&nbsp;21, and Supplement No.&nbsp;22, the
&#147;Supplements&#148;), which form a part of our Registration Statement on Form S-1 (Registration No.&nbsp;333-187508). This prospectus supplement is being filed to update and supplement the information in the Prospectus and the Supplements with
the information contained in our current report on Form 8-K, filed with the Securities and Exchange Commission (the &#147;Commission&#148;) on December&nbsp;1, 2014 (the &#147;Current Report&#148;). Accordingly, we have attached the Current Report
to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus, the Supplements and this prospectus supplement relate to the offer and sale of up to
125,000 shares of Series A Convertible Preferred Stock (&#147;Preferred Stock&#148;) which are convertible into 12,500,000 shares of Common Stock, warrants to purchase up to 6,250,000 shares of our Common Stock and 6,250,000 shares of Common Stock
underlying the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement should be read in conjunction with the Prospectus and the Supplements. This
prospectus supplement updates and supplements the information in the Prospectus and the Supplements. If there is any inconsistency between the information in the Prospectus, the Supplements and this prospectus supplement, you should rely on the
information in this prospectus supplement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Global Market under the trading symbol &#147;ABIO.&#148;
On December&nbsp;1, 2014, the last reported sale price of our common stock was $0.80 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a
high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;Risk Factors&#148; beginning on page 5 of the Prospectus and beginning on page 20 of our quarterly report on Form 10-Q for the period
ended September&nbsp;30, 2014 before you decide whether to invest in shares of our common stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
</B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is December&nbsp;1, 2014 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December&nbsp;1, 2014 (December 1, 2014) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-22873</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-3855489</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11080 CirclePoint Road, Suite 140, Westminster, CO 80020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 940-2200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5 &#151; Corporate Governance and Management </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02 &#151; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;1, 2014, ARCA biopharma, Inc. (&#147;ARCA&#148;) announced that Patrick Wheeler, ARCA&#146;s
Chief Financial Officer, has notified ARCA of his intent to leave his position at ARCA to pursue other career opportunities after having served ARCA for 9 years. Mr.&nbsp;Wheeler will remain with ARCA through December&nbsp;31, 2014 to assist in the
transition of his responsibilities. Mr.&nbsp;Wheeler&#146;s resignation was not the result of any disagreement with ARCA on any matter relating to its operations, policies or practices, or regarding the general direction of the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of December&nbsp;1, 2014, Brian Selby, age 53
was promoted to be ARCA&#146;s Vice President, Finance and Chief Accounting Officer and, as such, he will be ARCA&#146;s principal financial and principal accounting officer. Mr.&nbsp;Selby has been the company&#146;s Controller for 7 years and has
extensive experience in corporate accounting and finance. Prior to joining ARCA, he worked at several public companies, including as Controller for Myogen, Inc. and Controller for Genomica Corporation. Mr.&nbsp;Selby received his M.S. in Accounting
from the University of Colorado and received his B.S., in Business Administration and Finance from Colorado State University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective December&nbsp;1,
2014, Thomas Keuer, age 56, was promoted to be ARCA&#146;s Chief Operating Officer and, as such, he will be ARCA&#146;s principal operating officer. Mr.&nbsp;Keuer has been ARCA&#146;s Executive Vice President, Pharmaceutical Operations for the past
8 years. Prior to joining ARCA, Mr.&nbsp;Keuer served in a number of senior leadership positions in the biopharmaceutical industry including SVP of Operations for Insmed, Inc., VP of Engineering for Baxter Healthcare, and VP of Operations for
Somatogen, Inc. Mr.&nbsp;Keuer received his M.S. in Biochemical Engineering from Rice University and received his B.S. in Chemical Engineering from the University of Texas, Austin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the filing of this Current Report on Form 8-K, ARCA has not determined the final terms of the compensation arrangements with Messrs. Selby and Keuer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the press release announcing Mr.&nbsp;Wheeler&#146;s resignation and the promotions of Messrs. Selby and Keuer is attached hereto as Exhibit
99.1, the contents of which are incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces Management Transitions&#148; dated December 1, 2014.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: December&nbsp;1, 2014 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCA biopharma, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael R. Bristow</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Michael R. Bristow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces Management Transitions&#148; dated December&nbsp;1, 2014.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g829344ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA ANNOUNCES MANAGEMENT TRANSITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Westminster, CO, December&nbsp;1, 2014</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted
therapies for cardiovascular diseases, today announced three management team transitions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patrick Wheeler, ARCA&#146;s Chief Financial Officer, has
notified ARCA of his intent to leave the company in order to pursue other career opportunities after having served ARCA for 9 years. He will remain with the company through December&nbsp;31, 2014 to assist in the transition of his responsibilities.
Mr.&nbsp;Wheeler joined the company in 2006 and has held financial and senior management positions of increasing responsibility throughout his tenure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian Selby has been promoted to Vice President, Finance and Chief Accounting Officer. He will report to the CEO and be responsible for ARCA&#146;s internal
and external financial reporting, including compliance with the rules and regulations of the US. Securities and Exchange Commission, and corporate financing activities. Mr.&nbsp;Selby has been the company&#146;s Controller for 7 years and has
extensive experience in corporate accounting and finance. Prior to joining ARCA, he worked at several public companies, including Controller for Myogen, Inc. and Controller for Genomica Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thomas Keuer has been promoted to Chief Operating Officer. He will report to the CEO and be responsible for pharmaceutical operations, human resources,
facilities, and information technology. Mr.&nbsp;Keuer has been the Company&#146;s Executive Vice President, Pharmaceutical Operations for the past 8 years. Prior to joining ARCA, he served in a number of senior leadership positions in the
biopharmaceutical industry including SVP of Operations for Insmed, Inc., VP of Engineering for Baxter Healthcare, and VP of Operations for Somatogen, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Pat has been a tremendous asset to the Company over the past 9 years, helping shape our strategy, financing and development,&#148; said Michael R.
Bristow, President and CEO for ARCA. &#147;We are grateful for his service and contributions and wish him well in all his future endeavors. I am very pleased with the abilities of our people with such longevity within the company to continue the
leadership of the organization. I look forward to continuing working with Tom and Brian in their expanded roles. Their industry and professional experience will be valuable as ARCA continues the development of Gencaro as a potential treatment for
atrial fibrillation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ARCA biopharma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted
atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information please visit <U>www.arcabiopharma.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
&#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding, the potential for genetic variations to
predict individual patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on
management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the
risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; results of earlier clinical trials may not be confirmed
in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes.
These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2013, and subsequent filings.
The Company disclaims any intent or obligation to update these forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derek Cole </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">720.940.2163 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>derek.cole@arcabiopharma.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g829217img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g829217img001.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`$0`N0,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?\XH`HS:SIUO(8Y;M`XZCKBN.ICL/2?+*1K&C.2ND1?\)!
MI6<?;%_(UG_:>$_G'["IV#_A(-*'_+XGY&C^T\)_.'L*G8L6VIV5X2MO<([#
ML#S711Q5&O\`PY7(E3E#=%L'/2N@@*`#.*`$R*`%H`0$'I0`O2@!,@4`+0`=
M*`$R*`%H`3(H`6@!,CUH`4$4`%`!0`4`8?B>^DM+%(XFVO,2N[T'>O)S7$2H
MTN6.\CIP]/GE=]#D[>T,G(7)'4#K7R4(2FM&>C*2CL:=OI@D:+`X?]*].G@6
MVO,PE6L12Z=MBW;>2<``<UE4PCC#F*C5U,^6.2UE#(Q613P1U%<3YJ,U).S1
MK:-169WFE7;WFG03O@,PY^M?<86LZU*-1K<\FI'EDTB]TKJ,S-UW5$T;1;O4
M).D,9('JW8?G0!R'PN\1W&KZ?>6=_,TEY;RE\N?FVMSC\#Q0!Z!VH`PM>T>]
MO0;BQUN[L)8XSM6/:8R1SD@B@#SKP3J7B7Q;J=S:77B*YMXK:/<WE(NYCG&,
MXXH`W_$T'B3PGIK:OIVOS7D,)'FP7B*PVGN"`#0!T7@[Q,GBG1!>B+R9T;RY
MH\Y`8>GM0`WQ;XOLO"E@LTX\VYEXA@4\L?4^@H`Q=)TWQ/XF@2_US59M-MI1
MNCLK+Y&`[%FZT`7KCP(HA8Z?K^K6DY'#_:2XS[@T`5/`UQKL.JZOH^OW;W,]
MKL:)F_B0]QZB@#NATH`X_P"(^N2:-X6F6UE,=[='RHBOWE'\3#Z"@#0\$ZT-
M=\+6EV6S,J^7+DY.]>"?QZT`=#0`4`%`'->+AE;+C/S-_2OGL\VI_/\`0[L)
M]HJZ;;JY4A65AT8#(KFP-'FM8JK*Q?CN_,NGAAPB*W)QR3ZUV1Q//5=.EHKZ
MLQY+1NRW+$#\A8!MO#@=!]*[9P3]UF:;1SFH0J@;:C8]6'6OG,5",6TD=U*5
M]SHO#PQHL''K_.OHLK_W2!Q5_P"(S5/`S7I&!QWB!VUKQAI.@H=UO;_Z;>#M
M@?<4_4T`<6A_X0KXNN&_=V5ZW7MM?_!J`/9!Z4`,N.+:7_</\J`/&_A)<P6N
MOZNUQ.D(:+`+L`#\Y]:`.M^(6NVDOAZ;1["07NHWN$2&#YV`SR3CH*`+GP\\
M-W/AOP^8KWBZN7\V1`<A.,`4`<!*Q\5_%]8;C+6\,Y15/0(G./Q-`'MJJ!T&
M!]*`%(XH`A%K"+HW(B43E=A?')7TH`EZ>U`'#V]K'XM\6ZM=2_/I]C"UA#GH
M9&'SD?3I0!SGPNO9=)\0:GX:NB5.YB@/7<O!_,8-&P'KB]*`%H`*`.:\6G:+
M(@X^9OZ5\]G=TJ=O/]#MPF[*NFW`5E&YW;/"J<"N7!U8Z)-W[%UHLEEL;B.Y
M>:SVRQNW*AN0>XK:IAJGM'.EK%[KS)C.+CRST+=NLT69)R/-V_+&IYQ]:ZJ,
M:D+RF[M]/+U,YV?P[&-J$P<-LD?'HQKQL544OA9U4HM;G1>'C_Q)(#]?YU]%
ME?\`ND#AK_Q&:%S<Q6EM+<3-LBB4NQ/0`5Z1B>?^%M#N=?2\\23:C>64FHS%
MHQ`P7]T.%SD4`9'Q+\*O9:/!JPU"[NY('"$SL&*J>A&!ZT`=]X/UI==\,65[
MUDV^7*/1UX-`&S<?\>TG^X?Y4`>+_"S3;+4]:U:&^M8[F-8LA9%SC+GI0`FJ
MV=Q\,?&T6H62%M-N,[5ZY3^),^HZB@#V33[ZWU*R@O;5]\$RAU84`>,_\BO\
M7]]R-D,EP2'/3:_0_G0![>&'X4`*3B@"M/J%K;7-O;2S*DUP2(D/5L=:`,SQ
M9K:Z#X;O+[K*%V1+W+G@8H`Q-`\$S66BVRMK>H6\SKYLR1.`N]N3VH`XKQEI
MTW@WQEIVL0W$UPLA$AEE.69@<,"1[4`>SVUQ'=6T4\+!HY5#J1W!%`$U`!0!
MA^)K&2[LDDB7<\!+;?4=Z\C-<,ZU)2CO$Z</4Y):]3DX+MHAM#8SP:^4A4<.
MEF>C*"DKHTX-36-XER"J5Z,,9R.*Z(YY46R*74-T04GE22/45G4Q7/&U]BHT
MK,SY)'N90JKND<X`'4UQWG7FDM6S;2"U.\TNU:RTZ&!C\RCGZ]Z^VP=%X>C&
MF^AY-27--LXWQK-XBUS3+C1](T6=8Y#MEGE8+N4=EY[UUF9T/ABYG.F0V4VE
M3V#6L2IB3!4X&/E(ZT`5_&$L\^DW.EP:/<7S741`*8"*>V2>E`'&^"K?Q;X0
M62WNM"EN+"4[BL3J71L=1SSF@#N-6UJ_AM%6RT.[NIYX<J!A50GC#'/!H`\_
M\%:3XF\(:I<7=SH,L\-RFUQ%(I93G.0.]`'H&N:-%XM\-&VN(7MY)%WQ>8,/
M$XZ9H`XKP7'XO\*I-:7&AR7.G[R<)(`R'U4=P?2@#IO$GA2V\;Z1!-+%)8WZ
M*3$SCYE_V6'I0!0T75?$_AV%;#7](FO8(AMCO+3YSM']X=:`->7Q@&B86.BZ
MG=3=D,!0?B30!C:'8^)+GQ7/X@\0V/E)!;E;6"-PVW/8#UH`I>)/^$FU_5M.
MF7P[,-+LIA,87D4/*1W(H`]!T^\DOK19WM)K1B2/+F`##\J`.(^(5IJ7B*R&
MEV&AW$DL,P<7#%53&.<'OF@!WA*]\2:#I46EZMX?N)8X1B&:!E8[?[I&:`/0
MJ`"@!",T`49M(L;A]\ELA;UQBN2I@L/4ES3C=FBJSCLQG]@Z:/\`EU6L_P"S
ML)_(BO;U.XG]A:;_`,^JT?V=A%]A"]M4[D]MIMI9G=!`B-ZXYK>EA:-+X(V)
ME4E+=EH#`KH(*6H:BNGQQLT;R&1@BA?6@"Z#D?,,>U`%=+Q'OI+0)(&C4-N*
MX4@^AH`LY]Z`$SCITH`4$$`Y'YT`4;K45M;VVM?*=WG.%(Z#UH`N\#O0`N1Z
MT`'%`!GWH`.*`#(]:`#B@`R.F:`%H`*`"@`H`*`"@`H`*`$S[4`<]>R27NO+
M'$5$=DA=I&^ZK$4`7=-N;F725N)RID^8AC\H91T)H`32+N>XLIKJYD!B9B8_
MEQA!WH`HMJUV;2+4!A(Y9Q'%!C[ZYQD^]`%SQ!-+'9);PX#W3B$>HSW%`#-*
MEFAU&YTQI!+#;1IL<C!&>QH`@+37OB.=H6"QVD?E^81D(3R?QH`N:7?R-HPN
M[UP,%OFQC*@\&@"O<WUY)+:P0LL,EPV0F,LL8ZL?2@"77+VYL;:,VQ&]W"+Q
MDL?2@"W;1WRO(]S,CJRC9&JXVGTSWH`Q9-6O?^)C()D6"`;5<+GY_0>M`%BT
MO-1DOK.&5E#>5OG0+]T=LGU/I0!HW%X4G%M#@RD;F+?=C7U-`$&C7%S>K/<R
MR;H6<K"-N,J.]`&J!@4`+0`4`%`!0`4`%`!0`ASVH`R8]%"S7&ZX9K>:3>T>
MW&3Z$^E`%N]L_M=A):)(85==NY1T'I0`L-E'#9_9OF9"NTD]^,4`5+;1EAD@
M:69I5MAB%,8"^Y]30!5FWZEXAQ#,%6Q3(.-PWM[?2@#4L[)+)'VDO+(V^20]
M6-`%1-':.'R5NW$;LS3849DW>_:@"Q?:<EUIWV.-_(4;=I`SC'M0!!%HRQZB
M;QKF1W*A2#W(]_Z4`69K!;B^@N9&)\@'8G;)[T`6)HVD@>-9"C,"`P'(H`SU
MT2!8K.+>QAMFWE2/]8WJ:`'VFEBVO;BZ>9Y'F?=@\`>WO0!#=:)]HFO&-VZ+
M<J`5`'!'^>E`%ZPLULK980S-M`&3_AVH`M4`%`!0`4`%`!0`4`%`!0`4`%`!
>0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g829344ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g829344ex99_1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`3`#6`P$1``(1`0,1`?_$`+H```$$`@,!`0``````
M```````'"`D*!08!`P0""P$``@("`P$!``````````````,!!`(%!@<("0H0
M```&`0,#`@0$`@<)`0````$"`P0%!@<`$0@A$A,4"3$B%19!43(C81>!D;%2
M<B4*<:%",U,D-"881A$``@$"`P4%!`<%!@0'`````0(#`!$A$@0Q46$%!D%Q
M(C(3@9$4!_"AL<'1(PCA0E)R,_%B)#05%H*28]-#4V2T)A<8_]H`#`,!``(1
M`Q$`/P"[_GGD'3,!U]O)6`%I6<EC*I5ZK1RJ1)&640`!7<*JJ]R<?%M1.4%7
M!RF`!,!2%.<>W737SC^=G2WR9Y,FOYV&U/-]22--I(B!+,5MF8DX1PI<9Y&!
ML2%568VKEW2/1O,^K]8T&CM'I8[&25@<J7V``8LY[%%MER0,:C;D?<0S0_>G
M/"56@Q3(1$$6CAC.2ZY2=P]HK/?K,<150"_$2HD`?RUX)YI^NCYHRZEI.6\O
MY+IM)<Y4:.>9[=F9_7B!/<BCA7>,'R6Z8BB`U6HUDDO:P:-![%R-8?\`$:]1
M>='(@3&*>'QT4Q0`1#[>F^H&*!RF`1LW4IB&`0'\0'5%_P!;7SL5BOPG([C_
M`--/NN#_`)K81B.%!^471E@1)K<?^I'_`-JO2_YP<B6"Z[<\3CP3H*F2$!KD
MV!A$H[?I"SCU'\M.U?ZU/G?H]0^GET?),R,0?\-/?_W=+B^4O1DJAUDUN4B_
M]1/^U6'/[@6>XYV!7\!CIP1!02KMPA9U#R=H['3\Y+&<R1@'IN!1V'\-$7ZX
M?F[#JLFITG(W"-9D]#4+>VT9AJC8]E[&G?\`TUTC+'^5-K58C`YXS;V>GC3X
M^.G+RJ9R<#6)*/\`M"_I-CNB0JKH'<;.-T"`9TX@'YB(**JMPW,HV5(58B8=
MQ14*!C%]B_([]3?3OS>G_P!OZZ#_`$SK18RX@+YXM0JB[MII"%)*XEHG4.J^
M(%U#$=3]:_+?F'2:?'P/\3R<L!G`LT9.P2+B`#L#@V)P.4D`N^WUZ9SFNM[4
M;Z,YHM1OHSFBU)58LWXHJ>5,>X1L5WAXK*V58JT3>/J4X%R,M9HNEMD7ED=M
M!2;J-$"1[9;O`%U4C+@13Q`<4U`+'JV(4VS'9601BI<#PC;2J[ZG.:QM1OHS
MFBU-^R3RPXR8;MK:A99S]B+&UT>1C2::UB[WZMUF:6B'R[MLSDB,)>0:+^B=
M.&"Q"*;=IC)&`!Z#K$S*ILQ4&LUBD<9E4D5B3\T>'Z38'BG*?CN5L.X@L.9L
M>=H[!N/_`.AWZ!_#1ZZ?Q+4^C+_"WNK4VON%<%7L@2+:\ON.2K]13Q$0#+U(
M+W*;B7M!0\R5'?</[VVH^(C_`(EJ?0F_A;W4Z2M6NKW2)0GZ=9("V03H1!M-
M5J8CIV)<"4"F,"$E%N73-80*<!'M./00_/6><D7%B*45(-C<&L_OHSFBU&^C
M.:+4C>7>1&"<`QA9C->7\=8M8*I^5N>[VV&@'#Q,#&*)H]B^=I/Y#8Q1#]A)
M0>@ZAI0F+D#OK)8W?R`FF=K>[[[=:13KDY&Q[R.2$04FXW'N6I.O%[1V,?Z^
MPH;B',D&P_."PDV`>NE_%1;_`*C3?A9_X?K%;W5?<]]OFYD3/!<O<'""OZ"S
M-R9U=3IT'N2LX0ZJ8!MU[@#;4C4QG8R_76)T\PVJ:?*T=MG[5L^9.$'C)ZW1
M=M';94B[9TU<)E6;N&ZR9C)K(+I'`Q#%$2F*("`[:9G/"E6KT;Z,YHM7PHH1
M),ZJIR)IID,HHH<P$(0A"B8YSG,(%(0I0W$1$``-&<\*+4E^&\VXKY!T9IDO
M#-UB;_1GTI.PK6Q0P.RM%)2M2SN$FF@I/FS1VFHSD62A0$R92JD[5$Q,F<AS
M0LH<9EL163HR-E<6:E3WU.<UC:C?4AS8T5`?S(G)2T<D+PU>+'40KPP]<B4!
M,8R;2/;1#)Z<B11W`GJ7\@LL?;XF/_`-?&#]5_/]=SCYX\XBU;%H]#Z&E@6Y
MLD:PQR$`=F:21W-MI;A7K[Y8Z/3Z'HG2/$`'FSR.>UF+LN/<JJ!P%:_CW&:U
MG**$6CYIE%(RQ8OXKRJ"1146-%@;_G/FY"B8S8/G5(`F2`P@)==;='=#:KJM
MS%R]3)S=5+"#]Z=5%V]#^*51<F'S.H)B#$%:VW-^=)R\9]2<NE)L7[$)V9]R
MDX!]@.#6&-.;CL.FG*;'3C-IW/(B0^UIQ$$Q!4J+@2*P,@H3;<``%U&:@CU`
M44]_B.N]-#\K9>=]&P<^T,1;5:/5?`ZI0/$`Y#:64C:!XFT['L,<>\UPF;J5
M='S9]%,UHI8_6C/9<7$B@^P./YFW4H=MPF@PM^0[`X:E"&J@C(-2G(`)OIB0
M;MB5]B7<``Z97KDKA4`W`$DA`?U!KL'JSY0Q\MZOZCYYJH@.2<G_`#4N/#+J
M)E0:2(;QZCB5[?N1D'S"M'RSJHZCE>@T4;?XO5>$[U1"?58[O""HXMPIH-OQ
M:O%1B<Q+HG;IR13JQ#-4!*^ER%.8JLCV#^XWBB*`(><^WG4`2I`;8YB>7.H_
ME[JN4\N3G/,U:)-0"T"'"6<7QF`VK`#<>J1^:UUBS6=D[(Y?SV/4Z@Z33',8
MS9V'E0]BW[7M^Z/*,6M<`H569*3H][JECC%3MG\%9H:2:*IB)#`9O(("JD.W
M447"`F2.`]#$.(#T'7#>CN>:_IKJSEO.M$YCYCHM?!*A!MY9%N.YES(P[5)!
MP)KD7,=-!S3E.IT6H`:&6!U([U-CW@V(W$`U9D`=P`0^`@`_U]=?H%...^O"
M=&HHK@1`H"(B```"(B([``!U$1$>@``:**HB\\>9V3YSW"J;S>JK23#&&-\C
MNZGQOE3&.$+=*?@"TIP>2/I1NX`59W&?F)$'`B``HVD4R=0)TULLK&7U!L!P
M]E;>*)1#Z1VD8^VKQN/[Q7<FT6FY&J+TDC5KY5X&WUU\F)1*ZA;'&-9:-6'L
M,8"G,T=E[B[[E-N`]0ULKAAF&PUJ6!4E3M!K;M%122Y1P'A'-L<ZBLO8EQWD
MEF\CU8M7[RJ$'/.TF*Q52F192+]DM(QQB"L8R9VZJ2B1Q[B&*;KHRJV#`$5D
MKNGE)%4)>,6`L7V'W3J;Q[LM;:6'%3'E-?J2XK,MWNFTM5J3-W(T1#2QS&!9
M\S53K[=-R!S"+A,#%/N!C;ZN-5,X4^7-6XD<B`N/-EJ\U.<+.(%CK;NH2_%[
M`+BN/69V"T:CB6C,"D;J)@F/I7,?"-7C!<I0#M60436((`)3`(;ZV95"+%5M
MW5J1+*#?,U^^J=F=+#?_`&8_<;N$/QPL\\VQ,W7J5[#&\G)O7=:M^,K<W+(2
M='L;%=91&0=PKA!^RC94P#(M_"BMY1/Y`/KVOIIB$/A^T;C6R7+J81G\WW[Z
MO'5.R1URJU:M\.8YHBU5^&LD694H%4-'3D<VE&)E"@)@*<6SHNX`([#K8WN+
MC816J(L2-U03>[[[L\MQ1<EXW<<SLWG(6=B6<A:[>LS1F6N)H6;)_DK6-AU"
M+-YC(MA1,"S1!=-1NQ:G36426,NB35>>?T_`GG^S]M6]-IQ)^9)Y-V_]E9#V
M^?:1K<7'Q/*#G@S?<@.4U^1;VIU$Y:=KW.(QH60(1TRBY".FE'C6QW1N@</6
M*O"JM(]8?3LT4P1\RI%``,\N,AW]G[:)M2?Z<."#=A]!4Z[:&B&4:G#,XJ-:
M1"2`-4HILQ:H1J;8"]@-DV*21&I$`)T[`+V[=-M6;]WN%5+F]^VH-_=+]H/#
M'(/%%[RS@:AP6-^1-4@)6QMFU,BVL+7LM-XMDJ[?5:QUZ/30B@LDBV1.$?*(
MI)NA>"4CDRJ)Q\=::!74L@LXW;#5K3ZET8*YNA/NJ3#@U?T\H\-^+]\(90RE
M@P7C15Z*H'*J$HQJL;%RY%2*`4Y%22C%8IBB&X&`0'3D.:-6WJ*1,,LK#B:=
M3K*EU&=[K>=K7B;BW(X[Q0@[E<]\GIUIQ[PS`Q1TPFG<W=T%T;)*QQ#F)V'A
M*DF[,1?N*5!VJW,8P!UTJ=BL=E\[8"K&G0-)F;R+B:AW_P!.+R-^DRV;.(%A
M<BU%<0S%CU@Z/XCHOX_T%2R5"(I*?N>H*FE$NP2#J'C<F$.@CI&D?;&>\??5
MC6I<"3V'[JM<ZN5KZYU(V&BH'.09!_\`IO*QP!(^UB8[D62362.`0,-L4Z:A
M3%,&_P#3KXI?J&9O_P!"=1`92HUL6#`,I_P\&T&X->ONB#_\$Y>,1^0V(P/]
M1]E.)P[`U";7CTW#2?K$P19N=E,5TJ\O&%=@H4R"R\<N!Y*/434`!`Z#A0H"
M&_:4.NNU?E7R7I+G>I@AU4?,>5<W$B&+4Z,-J(1(""K-"UYHB&L0T4K`;<BC
M&N*]3:SFFBC=HV@U&DRG-'+9'RVQ`<>!KCL90>)I4);+4Q.Y`G:M5Y!&&CX=
M^2$L,[$M46$E<)V'[VDA)NED_(=LT3>>0B1$Q`QMA.<P[E*7LGJ3YK\YYCUQ
MK>F.F)TT>ETLRZ;6:O3HL,W,-5I[QRS.PN4029U14()L7=C=57CNAZ:TFFY-
M#S+F2--+(ADBC=BR01O8J@!M=BMBQ(L,``,27#)H+QL`U>S4C]SQ?F0=/(F:
M5^H%5%N8#E63.OW*$<);;EW$2"(;&`0UW;`VMY5T]#S'GVJ'-^3M*CRZ;5-Z
MURA!#`O=@Z[5N2IME92*X8S1ZC6M#HH_AM58JLD?@(O?`@6%CV["-H--QS=!
MU9%\^F)96PW&:D$TG1$TFXP%<9M%4"*,&_K/&\>.6[9H<A2IMA3*`=/(4=]=
M%_.;D_2^GYE/S?FLO,><\[U2K(`L?PFCCC9084]2TDCHD94*D)10!;U`;USC
MI'5\R?3II=*L&DT<9*XGU968&S'+=5!+7)9P3P-1K7%(IYAF*;=JS2+*,1*W
M:(BFF4`=I=NYU#K.%3!O^I0YS#^>O"7-FR\]A,:1Q1?$1V5%LH\8[22S'BS,
M>-=V:*XTK@EF;(V+&Y\IW6`]@`JQP7])?\)?[`U^@+L'</LKPZ=M?6BHJ-GW
M6.14[@+B79(G'AE5LV9_F8KCUA6.9CO)+W7)IU(9:39)D'S`I`P)W3E-4H?M
MNBH[[=P:5,Y2/#S-@*?IT#R>+RC$U''[HGM[P=#]J#$=6HS!-W8>$<97[`N_
M;$,=>9A)M%&+S5(%`">0Y929D0GEN[])6([_``TN>("``;4^A^NGP39M02=C
M?04L7^G[Y'AE;B#)X5F9$7-KXXVI:O-45C%%<V.+B=Y8J4L01-Y%4(]\$G'%
MZ;)I,DR[["`:G2MFBR]JGZC6&L2TF?L:IX-6*J4:D;1WT50OXH*)I>]O7U%3
MD23+S0S<)CJ'*F0N\QDP`W,<0*&XB`!^8CMK61?Y@?S5N)/\L?Y:O36Z]4J@
M03ZSWFW5JG5R,:J/I"=LTY&P<2S9HE$ZCAP_DG+9LFD4I1ZB;KK9&PQ)%N^M
M0%8FP!O5-+,.&KU[T/N07RY8)BYA#C)!KU#'TOG61C'K.J-J+26H-9N5@G+U
M!N6:L=JDG$@>'CDMU_"HBNY!!(%#!093J9B4\@POV6'TV5LU9=-``_\`4VVX
MFKD?97L4XZ[&J)FE4QM2NQNW[^\[:O4Z"V11\A_U&1C8X"]P_$0WU?P'\H'V
M"M;B[<2?MJBA[<\:\YO>ZW0K[E`P3BEBR1>>1-J1>D!PW<*5)K(6RLQ)T%`.
MF,;'39(EJFB(>,K9`J>W:&VM;"/5G!;?<_;6VG(B@(7L%A5^/6RK3T:**-%%
M=2*"+9(B#=%)N@D7M3103(DDF7X]I$TP*0A=Q^`!HHKMT45#%1)%/F3[L=ZN
M9#%D<.^W#2G&-:F.P+1\IR1RPDJ2\S"0'`R2CBHUJ-5C#"7YD'+<APV[]Q2"
M))R=JQBWMJT?RM,!^\Y^H5`?RP:/_;$]XA'+5=:K1]#>7^*SC',F1!00?8PR
MPM(1F5JXV3+\IDF;Q>>;H)]0(*:`[=`U5D'H:C,NR]_8:N1_GZ;*=MK>T;*N
M_14I'3D7&S<.\0D8F88,Y6+D&IP5;/HZ0;INV3QNH'11!RV6*<A@Z"4P#K88
M;1LK56(P.VLAJ1L-14%.>)"0:<G<J$8+O$UAL;(4RM%%2GW^@0PF$H)"`@([
M=1_AKXN?/W5Z_2_J(ZA^!>593K8R,A8'_+P;,M>N>C(89.@^7^L%*>@VVW_F
M/OIU^'[Q*0R;96T91D639(4C!78MT>RRC@"B`^)<-G$/&E,`;""BQE>NW8'Q
MUWY\K.MN:\C]*?J;JG5:;1(5/PFG8ZR=[?NMY]/"#L.>0OV9!MK@O4W)]/K,
MR<NY;&\IO^:X])!Q&QV]BA?[QI&<HUBVX<R+-V<L-+*42Y2CBU0TN5HJJ$7]
M=6-).(2?!#S!$R3%TN<I05$"+)@4Q#"/>!>L?FITEU/\L.NM7U3%H]4>BN;S
MMK8)?3).G.I8RMI]4%S>A*CLP`<A72Q4DA@O(^F^9\MZDY+%RYI8_P#5]+&(
M72X\?IC*)([VSJP`)MBIP(`L2I5'O5ORLLUK55:.W9'!TD'DJ=-5.'B453`1
M1R^?G*5N02%'<B0&%54VQ2%$1URGHKJ#J_YGZB'IOIJ.62*1E628@K!`I(!>
M24C(+#RH"9)&LJ*2:U/-^7<JZ<1N8<Q90R@E4N"[D8@*NWO)\*C$FU*OE.WJ
M(ME82MY'EZVZA6Z,.M69\BL"F8T<W39_]I+LR*M"F7\/?VNE$R_-N"FP@&NV
M_F=U?(D;<CZ:ZDUW+9]"BZ9M#JU;2B\""/\`+U$0:.[9<V6=E&-Q)8@#C/3G
M*U+#6<PT$6HCF8R":(B0^(EO$C6.%[70$X>7MJ,:_P`K.*SC9.5>OUU32;0!
M,X>'=IJAZM(#"DX!59%PF;^\0QBC^>OG_P!2\PYUJ.H88^9S3R2'4IBTA<'Q
MKL8,RL#O4D'?7>G*X=*ND9M.B!,AV+:WA.T6!'<0*L1$_03_``E_L#7WP&P=
MP^RO$QVU]:*BJ[N;6>6/<#]TI6E8+R37L=U;VWJRUF4KM9J'_,^KFY`WATFW
M?H?:BLU763N9A8]KZ=!55SNQ=PS@Y"F,8-JS9II\J$`1^W&KJE8=/=A<N=]L
M/I]M/9MW%SW%[W5+-2+7SQPU+UBX0$Q5[%%..&<+X9&#GH]Q%RK%3;+.X$=,
M71R"/Q#??3"DQ%BZV/\`=I0D@4@A#<?WJK:^VA=+'[>/NFO\`9$D"MH>Q6R>
MXR7IV8#-H]^[>2:*^+;@D1RH8$&DE/(QRB*AS"*;*74^80$1&I`3%/D;9>QJ
M[.!-I\R[=H^^KR>MA6JHU(VCOHK\_K"^-Z3E_P!WY;&62(%"T46Y<O\`-L59
M:^Y=/V2$HP+8LB/BMU'46[82*`%=M$S@9%9,VY`Z[;@.KC4-.%;86K<LQ73E
MEVA:D5]Y/VDZ1A'&R7);C%$6"/Q_5UVS#+N,'=BLMMCZU$OEDVL;D*JK6.1F
M)9C',9!4B$JW,X421(LFY2!,B:^[M1IU5<\>SM'WTC3:@NV23S=AJ3GV3.>,
M'R<P"UP?9RQ$+FS`,)'1,G&QC!C#L[GCU,Q(^NWZ,C8]%JS3>IJ=K*:(DF4I
M'_8N.Q7A"E=IY?43(?,/LWTC50E'SCR'[:F)R!6OO2AW:G>0$?NRHV2L^41$
M`2^O0SV+\@B&X@!/5;_T:?:X(W@_95539@=QJB;[-%B3P=[FN*:M=TS0[Y^M
MD_!\BB]***K"X.H63C6,>J13M,1PYL]>39%`>HJ+`'Q'6MTQRS@'MN*VVI&:
M`V[ZOP:V5:BC111HHHT6HIIO.3DQ$\0^*^8,\2"C<9.I5APVID>X$FTQ?YXQ
M8:EQ8)&ZKI*SSU%1P4H")6B2I_@4=8R/Z:%]WVTV&,RR!!]!46'M_<(N?6)>
M.%7F*9RWQSBR3S<I_/:^UJT<:&&1;8E<\CL&$J]^XKF_R)"NY6128@W*HF+9
M(K97O3*`["8R(HI5096`OCB+U8FEA:0AE)MAMM3*/>JX8<JR89K')O-V>:)G
MDV*)=I2GB50P0TQ/)P%0OT@BB,K*2;&Y6<LW%,;2W9(D0532].:0.H4WS'`5
MZF.3*)'8-;#`6IFEECS&-%*WQVWJ5;V0.2(9\X,4RLR\D+Z[\?W[C#MC*X6%
M5ZI"1"*3_'TBJ!A$XMUJ8];,RG$?G68*_B`Z?IVSP@=JX?A2-6F27-V-C^-3
M!Z>-AJK4`G+1%_`\ELEF<D41"0?P\FWZF*1PQ>0$5X%BCT*H03I'*/Q`#D$/
MB&OBM^J/E^LT/SUY_P"LI1I9H9DW/&^FARGB+JP_F4C:*]A_+B2'5=#Z'(0<
MB.IX,LCW'U@]Q%>K&61&M7.C*%3;O9A'M-$I.2%681:P?HE';<VZ;UXB/5L@
M8/$0X`HH!MBD'BO0'6T'2\Z<RR)-SB,W@$@#10MV3.APDD7;%&W@5K22!K*A
M?SOD\G,4.F)*:5O.0;,X_@!VJ#L9AB1@MKDT[B&S@]A:D4YY-=U8[C+_`%J6
M?N%_,Z"!BE/2LT%3*;F`95\1R(AT#TY-@#M/KTURGYR<SY%TF9!JI).I.<ZT
M:G43.^:3X73G)&A)N?SY?6)[/24`#*]==ZKI+3ZWF=O35>7Z2+TT4"R^HXNQ
M'\BY/^([Q6]V_+[5_.9!HQ5TDH]YLI4_")44X^?@V[9VU0;@EV%2+,^G41$0
M`!\YR#^(ZYSUC\V(N:\\ZCZ(,@7E<Y#:#+91#JM*J2(J9;!1J,CQFW_BLC=I
MK3<JZ7DT^BT'."I.H3">^.>*0E6)OM].X/\`*".P4S7(.5?NUHG]86*>=9H%
M;M9T1`JDFS3+LBQG/P6=-B]$'@_N=O[:O<4"G)Y-ZV^9+=5Z5?\`66S<]A0(
MFJ_>FC&"QZG^-T&$<_GRVCES*%=.S^3]/CEDI&D%M&QN8^Q&.UH]P.UDV7\2
MV-P6N,Q?66U0$0Q*HNYD[##,&K<G<;RNWDFU;(@4@;@)A.H`;ZZAY#H]9S?G
M^CT.G5FU.IUT$<:"^+O*BC#?<US34-%HN7S:B4@1QP.Q.X!23CW"K-0!L`!^
M0`']0;:_0>1;#=7@^FC<X>6-,X9\<[_F:T/X\LW'P[R-QS6G*Z17ESR'(-U$
M*Q`,&ACE7=I#('(N],0!],P266-L4FL9'])"YV]G?38HS*X4;.WNICWL7XO;
M5SA8GFR5F&]GR7R@R)>,MY(L8+E=/UI(MBE*\PB9%<ISF!RS+&KO%4C;&2=2
M*P"'72M,I$6;M8W--U;7ER=BBPJ9K3ZJU3'_`-0_AQMCCEABK.U8?HQDIF*A
M%-)D9KI)2C&Z8BD8U@PLY4DC%<)>IA)B,226$.JL:.QMPV"AK$LX;M(^RMGH
MVS1%3V'[:LO<`.7],YF<;<>Y*AI^)>7QM78F'R[5V[MN,Q4\AQ[-)I8$)&,*
M)7+-A+/D3O(]42>)PS7(8AA$#`%R)_50,/-V]]49HS$Y!\O93U'+ENS;KO'B
MZ+5HT15<NG3E4B#=LW0(95=PX75,5)%%%(HF.<P@4I0$1';3`,;]E*J@7Q.O
M=0+[Q=+ORMABD*;,<Q,GR$?95WK=&&<,+38+ZTKSTL@HH5J#267E6P(JB?L/
MYBB`]0UJXR!J`>S-6YD!^'(&W+5^*PU^#ML!-5>RQ;&=K=DB9""G8:20([CI
M>&EFBK&2CGS=0#)N&;YFN=-0@]#$,(:VEMXPK3@D&XVBJ(')7$V8/9MY^05S
MQ0X?&J+>2=7C#,I(*+FBKQBZ2=@UM&*[4Y3$H/'$2@L,4_`?WNP6D@0"G42$
MNL=7T\MUV;1Q'TP-;:-EU,-FV[#W[ZND<6>4^(N7N(ZUEW$=B8R;"8CFBD]6
MQ?-5;+1;`=$HR=4MD:D?U$;+Q3KO3W.0J;@A2K(B=%0AQV".LJYDV?6*UDD;
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M5HUXSH58K%69/5U4HNNPK6I*)MR)%("A1\AP%0QC#AI[M&7.+,Q-,U659`B^
M55`IC/N(YDH7-#W"N'/MVP]KB)'&].RJWR'GY=M*-SQ4Q;("'DYN-QAZHBAF
MKB8:5N->-ET2F.8CR:(B)?.@8@+E822K!V7Q[Z;`IBA:8CQ$6'T^FRK(I2%3
M*5,A2D(0I2$(0H%(0A0`I2E*``!2E`-@`.@!JV=N-4:1_D)AZO<@<'97PI:B
MI?0\F46Q5)TX6+WECEY./63C9@@#\'$))@B\2'_A50*/X:@KG4J=A%9HQ1PX
MV@U2Z]E;EO"\/^75AQUE6T1T#C',K13&UFL+M^FC5X/(=3F'84BSOGXG]&WA
MWCE5_&F=G,"*9)))50Y4B&,&NTT@CDLV"G#\*V>JC,D=U\PQ_&KSWKF7HOJ7
MK&OT[TOKOJ'J$?1>B\7J/6>K[_!Z7P?/Y.[L[.N^W76S`-C6IIJG*'B[&9[C
MV4O$/FU?R%!-CM8R5<IJ'C9:-,<ZWT6;*@4ZY$$USF40<)E.=`QSAV'*<0#S
M;^H3]/?+_G+HXN9<MFCT76VC0I%,X)BFB)+>AJ,MV"AB6CD4,T99O"RL178O
M077T_2$SZ;4HTW)IC=D!&9&V9TOA<BP938,`,01>HN7_`!(Y*5U^JT)CE_*%
M3,(%>0DM!OV"Y=^BJ*II%!8H&#\%$R'#\0`=?.?FWZ6OGIRW5MIUY%-.5.$F
MGF@DC;B#ZJM8_P!Y5;>+UW]!\R.A]7")#KDCO^ZZ2*P[QE(]Q(XUF2X'Y-''
M=3$]G``3313*#F&$$T44RI(I!_FVW:1,H!_O_'2I/D%^H,M?_;G,"`H4#-!@
MJC*H'YVP`??2O]Y]"C!>8P;2=C[2;D^3?7OE<)\G'\@YD"XKM(+K.1<D5!Q#
M%.54#@<AP'ZL(E,42@(?Q#5OF'R-_41KM?)K_P#;O,!,TN?-G@!OM!_K;01>
ME0]7=!Q0K">8:?(%M:S[/^2M4<<8>2\V\,4<5SK<72PB(N'\`W;$,J;<PG65
MERD33`PC_L#5%?TT_/77ZN\G3FL$DC7\4FG5`3MN3,`!?W5<'7_0VFCN.81$
M*.Q9"<-P"7)I]_%[A8MC2<99%R<ZCI*VQX&4KM=C#B[BZZZ43,F:3>OE$TRR
M,PDD<Q403)X&XB)P,H?M,3VM^GS]*<O0/-XNN/F!)!J.I8+G3::(YX=,Y%O5
MDD(`EG`)"!1Z<=RP9WRLO4/7WS07GND;DO(5>/ESX22-@\@_A5;G*A[;G,VP
M@"X,AVO;5=,5&A>/:.X293M4G=,M4[).5[%)OI-_ZW(>=LR60D8:6?*OW+2"
M;.;L5O"1J:JPE2;-BIHII%*0"[%#2C!$3=@2>^K`U,H%E(`X`5N&$?;,XI<<
M+U$7W",/D['KN(D5Y4*S#9ORRI095VX8.HXYK#1G]N>5R?(5!T)B@Z05V4(0
M_P`2%VE88T.90;]]8M/(ZY6L1W"_OI\UD@FEHKT]67[B3:,;%#2D$]=0LH^A
M)ELTEF*[!PXB9J,6;241)HHN!,@Z;J)KMU0*<ABF*`@S:+=AI0-C<;149$G[
M,O`>S2QI^_4#(N3IY1NDU5G,D9XS/;YA5%$!!-,\E)W<[OL()A,!`.!`,(B`
M!OI/P\)-R"?;3_BI@+*0.X"N(KV9.!56FD[)CZAY)Q=844RI)3F-<\YFJ$L1
M,H@;L^H1MV(Z,F(AN)#&$F_X:/AX1L!'MH^*F(L2".(%+UR&X`\?>4LPRE,S
M*Y;L#-G78ZL_:L9F_*=9I#UC&K.EDG4I4*_:(Z"E)=P+PP.':Z)UW!2E!0QN
MTNV3Q1N;M?9OK%)GC%EM[A3=E?9$]M%5J+7_`.>E4]TRI^H3R;E8KD.W;YP.
M-T,3O';^[M_#6/P\%O*??6?Q4^_ZA3MN-O#C#W%(TZGB)[E).,GF$;&GKUVR
M_D;(E;B&\6LY6;C6X.Z6&:CZ\NH+H2JG:D3,HF4I!^4H!K-(U3RW]IO2Y)7D
M\UO<*]?*7AUQ^YF5.NTSD!3%+9$5.PA9Z\LQF9>N3$5)F9+Q[HK6:@G;&238
MR+-?L<MP4\2_8F)BB9,@EET2097%P*B.5XB2G:*:A$^S-P&JSI*3H>/,AXUG
MDD?#]RXZSQFJH6%0NVP"K*Q-Z174$H]0`?E`?PU@((1L!![Z9\5,=I!'$"I0
M8Y@C&1S",14=+H1[)JP25?NEW[U9%H@1NFH\>NCJN7KI0B8"HJH8RBAQ$QA$
M1$=-&&RD'&HXLX^TEP<SG9S7]YBYYBS))I`)8,B8,LDIBNS$E0-W_502KZA:
M\:5,K\YG1F!G!SCN8XCI301.;D6;>,*<FIF06!NO'&L4U]MRW,F9(=M[C'N&
M$@$R>%..-F*H+OB-@#M!`MC<8Y5L(`!.@&]3WA^>CTCL]1[5/KC;Z:7[JUZ+
M]EC@@K..[7DVJ9.S_<)`P&D+;G+,V0[E.OS%'</5+LYN#;*D`?@F*7C#X=NW
M34?#PWN02>)J3JIK6%@.`IW-NX:X+M6$*GQR8Q5NQWAZE+H'@:EB/(EXQ@5-
MDBG)E&$>RU.G8N:DH)RK+K++-%W!TEE^U0X"8H"#"B,H3$*-QM2A*X8O@6.\
M7IHY?9(]MU))'TF#)9A(-UDW2$XPRSEMK.(O4E?.1^C(IW4%4GP+_/Y2@!P.
M'<`[]=+^'@W'WTWXJ??AW4__``?A&H\?Z0&/Z3+7^8@BR[^92<9'R';\FS[=
M:0(V3.R0L5VEIF92B6Q&I00:@MX41$PE*`G,(L50@RK>W$WI+N7-S:_`6I-.
M1W#C$'*E:('+,AE8T;$1,A"C7*1F/)&.JQ,L9)PBY<!9("E6*%C;"L!D>PBC
MHBABI&,3]([:AXT?S7]]JE)6C\MO:+TTDGLA^VB5GZ0>/:RG[0I"Y4R=E4SD
M0$-NX3A=`3[P#I^G;;\-8?#P6\I]],^*GOYL.X4J-;]KKB?5<69'PE&,<NJX
MFRE$UJ%LM!D\[Y:EJZU856TL;?&IUEE(6Q<*J9>5C4B.Q8"AZMH`MU>Y$YB#
MF(8PA7'*1LOQJ#J)"P<VS#MMPM4B.F-YC2*XU%%&BBC111HHHT44:**;#RPR
M?=,68W82F/'T2A<Y^UPE3K\?)0YIE>6?S:IT2-XY'U[5%NY;D(97R*I.4Q`O
M:)`$P&!,\C11ADMF)M_95K21)+):0'(!<XVI>Z?'3415:]&V276G["SB&",Y
M-+D03/)RY6Y!D78)-46[=))5V)Q3(0A2D)L&W33@&``?%K8FJ[E6<E!9;X"L
M#E,^24Z).GQ&C7W&0"I-_H*5G.J2',<7:`//.*9DP%8&(J"D!S%3%3M[AVUB
M_J9#Z5L_9?964?IYQZM\G"MK@1FC0<.:R$8)V$8M@,Z2*,J:,),"U2&2+'&7
M_?,R*\[P2$_S"3;?KJ1>PS>:V/?6+9<QRWRWP[JRVIL:QKSNW39@U<OGBZ;9
MFS;K.W;E8P$1;MFZ9EEUU3CT(FDD03&$?@`:.)V5(!)L-M8&G7*LY`KL?;:=
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M111HHHT44:**-%%&BBH[,CJ6S.?+:`IM*<(,X#`,2>6FK.Z;)2,?7KM8T"^)
M^WCU@]+*6&,9^(K!!;=))VFHJJ!DTC)GIR!IM2$38FT[B?OW5L8\D&D+OYI#
MLW@?=OI1.*_W2:Z\@BJWJX7_`!U$W6-K=/G+E*C,NG<Y#,G(70\:[*1%H#%M
M).$T!],FF@84P[2@)3:S@OGDQ+1WL"<<>VEZK+DC\*K(5N0,,.RL#E60R+=.
M2F-<6UB]3$.WA'Q<AW%E4GSB/BX;'\6HT!@TM"B12N9:PVZ4(HD"2IBLV[91
M("I'$ZBIB0R/.L2L0!B;=@X\34Q"--,TK*"3@+XW/#<![Z5ODOEZ>QA6*Y"T
M5JV>Y-R?9F5(H:+Q/SLV4@^,F1U..T!#M<(1*2Q!!,WRF54)W@)`,`YZB4QJ
M,G]1C84K30K*Q,G]-1<_A23^NL>+N1.!,8Q=TMMTD;?4[C(996L4Y(2R,P1N
MS%Q&6-.*<KJ1E:,UEV#@K9-BDW3*W'PF`X;#K'Q1ZA(P2Q8'-^/"F^&73R2,
MJJ`1EL+>SC[:V3FO:K3"8N95FHS"#"9RA/,L;LXU..]7*S"EF.5HX2:/#.R)
MQK)&-%<'!RH+*F,HF4AD_F$35,PCRJ<6-N^L=$B-*6<8*+]UJ2MO7I3`O(SC
MGBK'%HMKZO6&H32%VJ<K8).9K_TZ(9K]L^PB7Z[A"!.9X@LJ4&P))@8G:``!
MC`;#*8=1'$A)!&(OAW\*:6&HT\DL@&8'`VQ[K]M*1SIM$BRQ`SQY7DW+RTY@
MM,/1XF,8@`OWS11RF]E4VN_0OF302;&,/R@#GYOEWUGJV(AR+YG-J7H5!F]1
MO*@O269.JF3,:.>,;&!R%9FMOF<A5BG(TBO2BC/'L33HF,*>0B$8%%-/ZTC&
M1[4H/9%\*JKKN4.()$%---<J2)Z=F/J9K6&RPX=O?3(WCD]4LHR!2;G;<_38
M-E/<R=DAECF(CE2L%9ZSV:7;5JD5-HLF@^LUE?`<6S(BZA3D8QS5%,[AZ[.4
M4VC5,YQ`P]I36I'"8[238#>?IMJG%&9#N4"Y.X?393.LKEOMRRIBW!R>4;&I
M;;`Z+<\OM:6\&NU2J4"*%-Z2&C",TRS:2\D\*"*#AT[.Z6`2'4`I%2)EKRAV
MD6#,<QQ:V``^GOJY"8TB>?(,@P6^))^SZJ<SR+L<A3,16NRLK$M6&$'$/G$E
M(1^P6%P062S6(B:\]<%60C9&5GEVJ!W9R*J(H&4%(`5$BA'3L5B9E-@/?P`J
MKIE#S!2,Q)]GM]E-MP7BC,V1<3XJLMYS3DFI/(QXRL41%1DD*SJ=@5I-26.M
M='CX3/Y9Q.ME2I-$E5#(,8\"`*:BBBFR(8Y'B5G=@=H_;]VX59GEACE9412#
M@>_ANM]M*=S*O5@HF*GKN%LCROKS6]=A6]=,HE<9ZW2RB2,)'1;P$E!CHIFW
M*X=O#H!ZQ?PIH)G2!0QC9ZIRD1*FU]VTG<.&_MI6C17ELPO;''8!^.ZFI7A3
M.\,/&K&C;(5U?YXF#Q,N^K;.RNF]>@:A$)][E2]JMR&>V.2?+IJ'?.W*ITR(
MMED44]NTRM=Q.OIQAF]8XV[`.._V]F%6T]`^I)E7T!A>V)/#=P%+KAM6ZV?D
M_D)^TR-;[/1L=5U*JW%20D1^TYW)TDH#AZQJ]<1!.-@XJM()BF!4_,L0Z8>1
M905C',Z+,VH9LQ**+'<3P&RPJO-D73*"H#L;C>!Q/&G)Y"R')14_7L;T=JSE
M,C6UL[DFP2`*J0M1J\>JFA)W.R)MU$G"K)NX6*@S:D.FH_>&!,IR%*HH1[/9
MA&N,A^H;S^';5>.,%3(^$8]Y.X?CV4V6J$L&1N4AXV.R9=;11,&1"3NZN59-
M%A!3F59<7C9"&;L(!K&1_P!/B&A1.JU,"J2:S82#N8QS'2MWU%LQ9$Q/?[/L
MX59?+'I;E5$CG#>%WXT_C5FJ%<ZD;#11H;S&BN-111HHHT44:**-%%&@8&BF
M9TKCODZJ2V58U')4-'4[*-YEKC+S\)#/B945:RIA*I7V\R\=GA84J38QDR/4
MT'*Z7>8R()',!B5TAD0L`PR,;G#Q=VZKCZB)E4Y275;6/E[]YIUE4JM?I%>B
MJI58MM#0$(U(SCHYJ!O&BD41.<YSG,=5PX75,91550QE%53&.<PF,(B]0J`*
MHLH[*JN[.Q=S=C3=L78`M%5R5DK(MRNZ,VM=+H-D9LH-J[C%U(^/3<-:S$V&
M35<"X=1,`S<?M1R($:F<%*JJ9;L3(14<161I&:Y)OA]5_P`*LRZA'C6-%L`+
M8_7;OW[:WC+^)W=^FL87.#>1S>U8GM+BQPC2;!U]#ETI%CZ"0CI%9B15ZQ/L
M1)9!PFFL*:J(`*9BF';*2/.586S*;X[*7#*(PR,/"XMAM%=&-L,J5NZVK+5X
MEV]JRE<$4HY>1:-5&<#5*TU$@LZI4F3A5=TDP2%,IEW"QQ7=*!W&`FXE$2/*
MQD8WE/;V`;A1)-F01(+1#WD[S3=KTG9LR<N8F,J"T.I'<::^VL;A*>!X>!?W
MJU'3\<8Y<1Y57#)RC$^-1-8J:QD%FIMTS;B&D/FEU0"VM&+X[+FK$96'2DO>
M\AMAML*<I0L2+0UVL66+Q*-;-DRRL6\*1VR:JM("H59H?RMJO5&CE5=T1L=?
M=5V[6/YW:P]PE3+\FGJEG,CF\A]P&X57DE#((HQ:(>\G>:Q]TP_,VS+]9RA]
MQQZ+>AT>RQ5)@7<2H]2C[S8@.@-M?',[32<H,V0)D*@0A#B)=P.&H:,M*)+C
MPC`<=]2DRI"8K&[,+G@.RNW'N,;BG,0EZS-9X6[9"KT&^K\$XKT,I"5R$:R:
MY5)B49L'"RRBMBG44$47+D"H)D;I`DDD4#*&4E4:X>4AG`M@+`?MXU$DJ93'
M""L9-S<W)_8*P&7,.9`NV5<59&I5ZAZJ%`96=@Y0F()6P&+]RMTF;F2B6!G+
M=BI)^A`R93+F*5,0(;YP`Q!B2-VD61&`*W[+[:RAFC2)XW4G-;MMLWUJ&,N+
MTS2<LY"R!+WUQ,1ELEX:1;)ID=EMTBE#B5TDRL]D.LG_`):K*%(NY:,TDDG9
MD$2&$C8@MC81Z<I*TA:ZD^WVG\*SEU2O$L86Q`]GL'X_;2I9XP\ZS;#U*IN)
MU*)J+*Z1%CNT=Z15=U9X:&\JZ4`W<)N$4V2;IX8IE#G*H``0!`-PTR6/U0%)
MLN:YXTJ"80%GM=\MAP.^EP112;I)-T$DT4$$R(HHI$*FDBDD4")I)ID`"D33
M(4```````TRD4@]NPPZO.:Z'D>R3C5W3\:Q3U>KTD&"HF&[/U>T]HD'IW(H*
M^A:II>F3*D!DU4BFW^.ZFCSRK(Q\"C`<=]6$F$<+1J/&QQ/#=6)K&#IR%N>9
M\HR5I82F2,B-G<-3)@(I5)G0:VU8J-Z]%-T5G3A1P*+L$5GAB]@+F1#8`W-N
M+&P=Y"09&%@=U2TZLB1`6B7:-Y[:^.-^")7"M4:1EBM1+%-%&66=?24',="*
M/YR1+(RLN\3<+*.Y^P/CHHIF>NNT4FZ)$D4D@%4RL0Q&);,;GZOVFC4SB9KJ
M++]?=P'"L3*X)R"^SK=LDQN2T("I7>I5ZKR,<PB3K7!HR@R")X^"FG"OI(%N
M\=G56.Y2(HN`KF["D4`BQ8,3F4R!K*PMQK)9XQ`(RMW4D\/;OKIXS<<IC!\2
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MG^I>H_\`8?K/_D=G@_8[=^_IV:K:?T<S9/4O?Q7W\>VK>J]7(GJ>G:WARWV?
M93XNFK7@XU2QHZ:/!QHQHZ:/!QHQHZ:/!QHQHZ:/!QHQHZ:/!QHQHZ:/!QHQ
MHZ:/!QHQHZ:/!QHQHZ:/!QHQHZ:/!QHQHZ:/!QHQHZ:/!QHQHZ:D9+&BO__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
